Mazdutide (GLP-1 / Glucagon Dual Agonist)
$295.00Mazdutide (IBI362) combines GLP-1 appetite suppression with glucagon receptor activation to accelerate basal energy expenditure and reduce visceral adiposity.
Available: 4mg Weekly, 6mg Weekly, 9mg Weekly
In Stock (45 available)
Why Choose Mazdutide?
Dual-action mechanism specifically targeted at melting stubborn abdominal and visceral fat deposits.
How to Use
Inject subcutaneously once weekly into the thigh or abdomen.
Safety Information
Ensure adequate hydration and periodic metabolic monitoring.
Potential Side Effects
Mild gastrointestinal adaptation, occasional nausea, and early fullness.
Product Facts
| Generic Name | Mazdutide (IBI362) |
| Brand Name | Mazdutide |
| Type of Medication | Dual GLP-1 / Glucagon Receptor Agonist |
| FDA Approval Date | May 10, 2024 |
| Indications | Dual agonist engineered to reduce visceral and liver fat while delivering robust body mass reduction. |
| Dosage Forms | Prefilled pen for subcutaneous injection (4 mg, 6 mg, 9 mg) |
| Administration | Once weekly subcutaneous injection |
| Special Precautions | Promotes thermogenesis and hepatic lipid reduction alongside strong appetite control. |
| Drug Interactions | Slows gastric emptying rate. |
| Use in Specific Populations | Supervised clinical administration advised. |
| Prescription | Prescription Required |
| Manufacturer | Innovent Biologics / Eli Lilly |
How to Buy
Select your weekly dose and complete your secure order online.